BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 10317551)

  • 1. The impact of DRGs after year 1: management learns to cope. Part II.
    Becker BL
    MLO Med Lab Obs; 1984 Dec; 16(12):43-50. PubMed ID: 10317551
    [No Abstract]   [Full Text] [Related]  

  • 2. The impact of DRGs after year 1: first steps toward greater lab efficiency. Part 1.
    Becker BL
    MLO Med Lab Obs; 1984 Dec; 16(12):32-8. PubMed ID: 10310961
    [No Abstract]   [Full Text] [Related]  

  • 3. Stat testing and DRGs: a strategy for cost containment.
    Sazama K
    Pathologist; 1985 Apr; 39(4):28-31. PubMed ID: 10317591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of DRGs after year 2. Consolidating the changes; evaluating the tactics.
    Becker BL
    MLO Med Lab Obs; 1985 Dec; 17(12):26-32, 37-41. PubMed ID: 10317740
    [No Abstract]   [Full Text] [Related]  

  • 5. The impact of DRGs on New Jersey labs.
    Becker BL
    MLO Med Lab Obs; 1984 Jan; 16(1):30-2, 35-8, 41. PubMed ID: 10310867
    [No Abstract]   [Full Text] [Related]  

  • 6. Managing and reducing lab costs.
    Bernstein LH; Davis G; Pelton T
    MLO Med Lab Obs; 1984 Feb; 16(2):53-6. PubMed ID: 10317428
    [No Abstract]   [Full Text] [Related]  

  • 7. Test menus and profiles: signs of change under DRGs.
    Becker BL
    MLO Med Lab Obs; 1985 Apr; 17(4):26-33. PubMed ID: 10317588
    [No Abstract]   [Full Text] [Related]  

  • 8. The impact of DRGs. Part II: After five years, coping comes naturally.
    Gore MJ
    MLO Med Lab Obs; 1988 Dec; 20(12):31-5. PubMed ID: 10318155
    [No Abstract]   [Full Text] [Related]  

  • 9. Part one: How do hospital directors plan to cope with the constraints of DRGs?
    Lantos RL
    Pharm Times; 1984 Apr; 50(4):66, 68-9. PubMed ID: 10310561
    [No Abstract]   [Full Text] [Related]  

  • 10. The impact of DRGs. Part I: A five-year overview.
    Gore MJ
    MLO Med Lab Obs; 1988 Dec; 20(12):26-30. PubMed ID: 10318154
    [No Abstract]   [Full Text] [Related]  

  • 11. The impact of DRGs after year 3: Part II. How labs continue to cope.
    Hallam K
    MLO Med Lab Obs; 1986 Dec; 18(12):33-6. PubMed ID: 10311792
    [No Abstract]   [Full Text] [Related]  

  • 12. DRG strategies from the Big 8.
    Brennan L
    MLO Med Lab Obs; 1985 Jan; 17(1):45-51. PubMed ID: 10311089
    [No Abstract]   [Full Text] [Related]  

  • 13. Reducing hospital laboratory costs.
    Erhart PP
    Bull Am Coll Surg; 1980 Jun; 65(6):4-6. PubMed ID: 10316980
    [No Abstract]   [Full Text] [Related]  

  • 14. DRG opportunities knock for reference labs.
    Brennan L
    MLO Med Lab Obs; 1984 Apr; 16(4):30-42. PubMed ID: 10310555
    [No Abstract]   [Full Text] [Related]  

  • 15. DRG cost-per-case management. Labs should try to cut patients' stay, market testing services.
    Nathanson M
    Mod Healthc; 1984 Feb; 14(3):146, 148. PubMed ID: 10317429
    [No Abstract]   [Full Text] [Related]  

  • 16. Hospitals turn to new software, hardware to cope with DRGs.
    Jackson B; Jensen J
    Mod Healthc; 1984 Sep; 14(12):109-12. PubMed ID: 10310778
    [No Abstract]   [Full Text] [Related]  

  • 17. 101 ways to cope with DRGs.
    Wall MA; Miller KS
    OH; 1984; 28(10):8-11. PubMed ID: 10310964
    [No Abstract]   [Full Text] [Related]  

  • 18. DRGs and variance analysis: Part II.
    Wilson CN
    Hosp Pharm; 1984 Sep; 19(9):631-2. PubMed ID: 10310772
    [No Abstract]   [Full Text] [Related]  

  • 19. [Methods of calculating the costs of laboratory analyses and indices of the economic efficacy of the work of clinico-diagnostic laboratories].
    Men'shikov VV; Delektorskaia LN; Lukicheva TI; Fel'shina EI
    Lab Delo; 1990; (2):54-8. PubMed ID: 1692372
    [No Abstract]   [Full Text] [Related]  

  • 20. DRGs from the hospital administrator's point of view.
    Wood TJ; Thomas SE
    Aust Health Rev; 1985; 8(2):126-31. PubMed ID: 10311262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.